The aims of the study are to: * explore whether platelet reactivity in patients treated wih novel platelet inhibitors is associated with clinical outcome * investigate whether a therapeutic window exist for novel platelet inhibitors * investigate the incidence of adverse events under treatment with novel platelet inhibitors in the real life clinical scenario * investigate the association between genetic polymorphisms, inflammation, platelet reactivity and clinical outcome * investigate synergistic effects between aspirin and novel platelet inhibitors
Study Type
OBSERVATIONAL
Enrollment
1,000
Medical Univerity of Vienna, Department of Cardiology
Vienna, Austria
RECRUITINGNet clinical benefit.
A composite of MACE and BARC=\>2 bleedings.
Time frame: 1 year
MACE and Major bleeding
MACE: the composite of stent thrombosis, cardiac death and myocardial infarction. Major Bleeding: BARC =\>2, TIMI major, GUSTO moderate-severe-life threatening.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.